248 related articles for article (PubMed ID: 23104210)
1. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
Taylor KL; Shelby R; Gelmann E; McGuire C
J Natl Cancer Inst; 2004 Jul; 96(14):1083-94. PubMed ID: 15265970
[TBL] [Abstract][Full Text] [Related]
5. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
[TBL] [Abstract][Full Text] [Related]
6. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
Pierre-Victor D; Pinsky PF
JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
[TBL] [Abstract][Full Text] [Related]
7. Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Loomans-Kropp HA; Pinsky P; Cao Y; Chan AT; Umar A
JAMA Netw Open; 2019 Dec; 2(12):e1916729. PubMed ID: 31800071
[TBL] [Abstract][Full Text] [Related]
8. Impact of lung cancer screening results on smoking cessation.
Tammemägi MC; Berg CD; Riley TL; Cunningham CR; Taylor KL
J Natl Cancer Inst; 2014 Jun; 106(6):dju084. PubMed ID: 24872540
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
[TBL] [Abstract][Full Text] [Related]
10. Dietary fiber intake and the risk of bladder cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort.
Luo J; Xu X
Carcinogenesis; 2020 Jun; 41(4):478-482. PubMed ID: 31872237
[TBL] [Abstract][Full Text] [Related]
11. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.
Zhu CS; Pinsky PF; Kramer BS; Prorok PC; Purdue MP; Berg CD; Gohagan JK
J Natl Cancer Inst; 2013 Nov; 105(22):1684-93. PubMed ID: 24115361
[TBL] [Abstract][Full Text] [Related]
12. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.
Kirsh VA; Hayes RB; Mayne ST; Chatterjee N; Subar AF; Dixon LB; Albanes D; Andriole GL; Urban DA; Peters U;
J Natl Cancer Inst; 2006 Feb; 98(4):245-54. PubMed ID: 16478743
[TBL] [Abstract][Full Text] [Related]
13. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
[TBL] [Abstract][Full Text] [Related]
14. Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.
Pinsky PF; Kramer BS
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26483244
[TBL] [Abstract][Full Text] [Related]
15. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Kitahara CM; Berndt SI; de González AB; Coleman HG; Schoen RE; Hayes RB; Huang WY
J Clin Oncol; 2013 Jul; 31(19):2450-9. PubMed ID: 23715565
[TBL] [Abstract][Full Text] [Related]
16. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.
Tammemagi MC; Freedman MT; Pinsky PF; Oken MM; Hu P; Riley TL; Ragard LR; Berg CD; Prorok PC
J Thorac Oncol; 2009 Jun; 4(6):710-21. PubMed ID: 19404219
[TBL] [Abstract][Full Text] [Related]
17. Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Pinsky PF; Kramer BS; Reding D; Buys S;
Am J Epidemiol; 2003 May; 157(9):792-9. PubMed ID: 12727673
[TBL] [Abstract][Full Text] [Related]
18. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
19. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Miller AB; Yurgalevitch S; Weissfeld JL;
Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
[TBL] [Abstract][Full Text] [Related]
20. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
